Rx Price Reports To Medicare, Medicaid On IG Study List For 2005
Executive Summary
The HHS Inspector General will conduct several reviews of drug manufacturers' price reporting for Medicare and Medicaid, IG's fiscal 2005 work plan says
You may also be interested in...
Authorized Generics’ Impact On Medicaid Pricing To Be Focus Of HHS Study
The HHS Inspector General will initiate a study in fiscal 2006 examining the effect of authorized generics on Medicaid drug pricing and rebates
Authorized Generics’ Impact On Medicaid Pricing To Be Focus Of HHS Study
The HHS Inspector General will initiate a study in fiscal 2006 examining the effect of authorized generics on Medicaid drug pricing and rebates
Average Sales Price Final Rule Includes PhRMA’s Estimation Method
The methodology for estimating drug price concessions when submitting average sales prices for Medicare Part B will follow a proposal made by drug manufacturers in comments to the interim final rule